The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 10, 2017
Filed:
Aug. 05, 2011
Applicants:
Vikas P. Sukhatme, Newton, MA (US);
Jian-guo Ren, West Roxbury, MA (US);
Inventors:
Vikas P. Sukhatme, Newton, MA (US);
Jian-Guo Ren, West Roxbury, MA (US);
Assignee:
Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/11 (2006.01); A61K 39/395 (2006.01); A61K 31/196 (2006.01); A61K 31/282 (2006.01); A61K 31/336 (2006.01); A61K 31/506 (2006.01); A61K 31/56 (2006.01); A61K 31/7052 (2006.01); A61K 31/7105 (2006.01); A61K 33/24 (2006.01); A61K 38/52 (2006.01); A61K 45/06 (2006.01); G01N 33/574 (2006.01); A61K 31/198 (2006.01); A61K 31/335 (2006.01); A61K 31/337 (2006.01); A61K 31/555 (2006.01); A61K 31/713 (2006.01); A61K 33/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 31/196 (2013.01); A61K 31/198 (2013.01); A61K 31/282 (2013.01); A61K 31/335 (2013.01); A61K 31/336 (2013.01); A61K 31/337 (2013.01); A61K 31/506 (2013.01); A61K 31/555 (2013.01); A61K 31/56 (2013.01); A61K 31/7052 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 33/00 (2013.01); A61K 33/24 (2013.01); A61K 38/52 (2013.01); A61K 45/06 (2013.01); G01N 33/57484 (2013.01); C12N 15/1137 (2013.01); C12N 2330/51 (2013.01); C12Y 101/01037 (2013.01); G01N 2333/904 (2013.01); G01N 2500/10 (2013.01);
Abstract
The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing cancer and other related diseases that result in dysregulation of malic enzyme 2. In particular, the methods and compositions include combination therapy, such as with a combination of two or more ME2 inhibitors or a combination of an ME2 inhibitor and an anticancer agent.